KarlT
#8
Is anyone taking Urolithin-A? Rather expensive.
1 Like
A new paper:
Urolithin A Produced by Novel Microbial Fermentation Possesses Anti-aging Effects by Improving Mitophagy and Reducing Reactive Oxygen Species in Caenorhabditis elegans
Urolithin, intestinal microbiota metabolites of ellagitannin-rich foods, exhibit anti-aging activities. However, urolithin A is significantly superior to other types of urolithin with regard to this anti-aging function. This study aimed to screen edible urolithin A-producing strains of bacteria and explore the corresponding anti-aging efficacy of fermented products produced by these strains using Caenorhabditis elegans as a model. Our results showed that the Lactobacillus plantarum strains CCFM1286, CCFM1290, and CCFM1291 converted ellagitannin to produce urolithin A; the corresponding yields of urolithin A from these strains were 15.90 ± 1.46, 24.70 ± 0.82, and 32.01 ± 0.97 μM, respectively. Furthermore, it was found that the pomegranate juice extracts fermented by the CCFM1286, CCFM1290, and CCFM1291 strains of L. plantarum could extend lifespan by 26.04 ± 0.12, 32.05 ± 0.14, and 46.33 ± 0.12%, respectively, by improving mitochondrial function and/or reducing reactive oxygen species levels. These findings highlight the potential application of this fermentation in the subsequent development of anti-aging products.
Full paper (open access):
https://pubs.acs.org/doi/10.1021/acs.jafc.3c01062
4 Likes
Bicep
#11
I ordered a couple different varieties of yellow raspberries, so it looks like now I will need the CCFM1291 strains of L. plantarum in order to complete the plan.
Anybody know where to find this? I have only very time consuming methods.
1 Like
More on Urolithin A, from the company/people that first researched it. (I’ll wait for the third party validation, and a lower cost).
Urolithin A induces cardioprotection and enhanced mitochondrial quality during natural aging and heart failure
Cardiovascular diseases remain the primary cause of global mortality, necessitating effective strategies to alleviate their burden. Mitochondrial dysfunction is a driving force behind aging and chronic conditions, including heart disease. Here, we investigate the potential of Urolithin A (UA), a gut microbiome-derived postbiotic that enhances mitophagy, to ameliorate both age-related decline in cardiac function and cardiac failure. We highlight the significance of targeting mitochondria, by comparing gene expression changes in aging human hearts and cardiomyopathies. UA oral administration successfully counteracts mitochondrial and cardiac dysfunctions in preclinical models of aging and heart failure. UA improves both systolic and diastolic heart functions, distinguishing it from other mitochondrial interventions. In cardiomyocytes, UA recovers mitochondrial ultrastructural defects and decline in mitochondrial biomarkers occurring with aging and disease. These findings extend UA?s benefits to heart health, making UA a promising nutritional intervention to evaluate in the clinic to promote healthy cardiovascular function as we age.
Competing Interest Statement
J.F., C.T., D.D., are employees, P.A.A. was an employee of Amazentis SA, which holds patents on Urolithin A applications.
Sophia Liu, Julie Faitg, Charlotte Tissot, Dimitris Konstantopoulos, Ross Laws, Guillaume Bourdier, Pénélope A Andreux, Tracey Davey, Anurag Singh, Chris Rinsch, David J Marcinek and Davide D’Amico
bioRxiv. posted 24 August 2023, 10.1101/2023.08.22.554375
2 Likes
I bought Ultrapome developed by Harvard Medical School researchers.
Ultrapome (Amazon UK)
1 Like
I went ahead and bought the Mitopure anyway. Going to try both the prebiotic and postbiotic options.
Just started from Timeline. Yes, too pricey. Too early to say if beneficial but hoping will mitigate some negatives of my Metformin for longevity use. This is my IPad profile ( @Financial_Term_Struc ), but I’m also @Walter_Brown
1 Like
A new paper (open access):
The aging of an organism is hallmarked by systemic loss of functional tissue, resulting in increased fragility and eventual development of age-related neurodegenerative, musculoskeletal, cardiovascular, and neoplastic diseases. Growing scientific evidence points to mitochondrial dysfunction as a key contributor in the aging process and subsequent development of age-related pathologies. Under normal physiologic conditions, the body removes dysfunctional mitochondria via an autophagic process known as mitophagy. Urolithin A (UA), a metabolite produced when gut microflora digests the polyphenol compounds ellagitannin and ellagic acid, is a known inducer of mitophagy via several identified mechanisms of action. The primary objective of this scoping review is to identify and summarize the clinical relevance of UA supplementation in the prevention of age-related pathology and diseases. A computer-assisted literature review was performed using PubMed and EMBASE for primary source research articles examining UA supplementation and aging-related pathologies. A total of 293 articles were initially identified from a database search, and 15 articles remained for inclusion in this review, based on predetermined criteria. Analysis of the 15 identified publications demonstrated that UA holds potential as a dietary intervention for slowing the progression of aging and preventing the development of age-related disease. This review also illustrates the potential role that mitochondrial health and inflammation play in the progression of age-related pathology. Identifying the clinical relevance of UA supplementation in the prevention of age-related pathology and diseases will help further the focus of research on treatments that may improve the longevity and quality of life in patients at risk for these comorbidities.
4 Likes
Bicep
#19
Why did they use a colonic infusion? Does ellagitannin break down in the gut?
Neo
#20
Some thought on that here:
2 Likes
Thank you for bringing the good news about Urolithin A. I’m ready to start taking it, and also, would a daily dose of 1000mg offer greater benefits?
I’m not sure that’s good news. Most trials are outside the inner circle so they are no significant changes.
In particular that shows again that there are mostly no significant clinical outcomes and only in-vitro ones.
2 Likes
However, there is no double-blind study on whether weekly administration of rapamycin, coupled with the uncertainty of weekly administration, prolongs human lifespan or improves certain inflammatory markers.
AnUser
#25
Didn’t the Mannick study at least show an improvement in immune function?
Yes, one phase 2 study did, for ResTORbio, but then the FDA changed the endpoints for the phase 3 trial and that trial the drug failed.
2 Likes
LukeMV
#27
5 Likes